ClinicalTrialsFinder
RecruitingPhase 1NCT06468098

A Study of IBI363 in Subjects With Advanced Malignancies

Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IBI363 Combination Therapy in Subjects With Advanced Malignancies

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Enrollment

556 participants

Start Date

Jun 15, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Malignancies

Summary

This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IBI363 + Investigator's Choice SOC and a drug called IBI363 + chemotherapy for people with advanced malignancies. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIBI363 + chemotherapy

In this group, patients will receive IBI363 and chemotherapy

DRUGIBI363 + Investigator's Choice SOC

In this group, patients will receive IBI363 and Investigator's Choice SOC

Locations(1)

Shanghai Chest Hospita

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06468098

Related Trials

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

NCT0640135615 locations

Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

NCT076440396 locations

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

NCT074267574 locations

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

NCT0475282625 locations

A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

NCT060380581 location